Increased Rosuvastatin Dose versus Concomitant Fenofibrate and Rosuvastatin Therapy to Achieve Lipid Goal in Patients with Diabetes or Atherosclerosis with Metabolic Syndrome

PUPOSE: We aimed to ascertain whether increased rosuvastatin dose is non-inferior to concomitant fenofibrate and rosuvastatin therapy in patients with diabetes or atherosclerosis with metabolic syndrome. METHODS: After treatment with rosuvastatin 5 mg/day for 12 weeks, 112 patients were randomly ass...

Full description

Saved in:
Bibliographic Details
Published in:Zhonghua Minguo Xin Zang Xue Hui Za Zhi
Main Authors: Chen, Yeh-Peng, Chang, Kuan-Cheng, Tseng, Wei-Kung, Yin, Wei-Hsian, Chen, Jaw-Wen, Lee, Yuan-Teh, Wu, Chau-Chung
Format: Artigo
Language:Inglês
Published: Taiwan Society of Cardiology 2013
Subjects:
Mini Forum for Metabolic Syndrome
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC4804791/
https://ncbi.nlm.nih.gov/pubmed/27122739
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items